This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hesketh, P. J. Search for Related Content PubMed PubMed Citation Articles by Hesketh, P. J.

Defining the Emetogenicity of Cancer Chemotherapy Regimens: Relevance to Clinical Practice

St. Elizabeth's Medical Center, Boston, Massachusetts, USA

Correspondence: Paul J. Hesketh, M.D., Division of Hematology/Oncology, St. Elizabeth's Medical Center, 736 Cambridge Street, Boston, Massachusetts 02135, USA. Telephone: 617-789-2317; Fax: 617-789-2959; e-mail phesketh{at}aol.com

Significant progress has been made in recent years in developing more effective and better tolerated means to prevent nausea and vomiting induced by cancer chemotherapy. The most significant development has been the introduction of a new class of antiemetic agents, the selective antagonists of the type 3 serotonin receptor. With the new antiemetic therapeutic options and their attendant higher costs has come a need to define evidence-based guidelines to assist in their judicious and cost-effective use. A number of predictive factors for antiemetic risk have been defined. Some of these factors relate to the patient population (age, gender, history of ethanol consumption, and prior experience with chemotherapy), and some relate to the treatments administered. Clearly, the most important of all these factors in predicting risk of emesis is the intrinsic emetogenicity of the chemotherapy. Although an "ideal" emetogenic classification schema for chemotherapy has yet to be realized, recent developments in this area have allowed a more precise estimation of emetogenic risks and have provided antiemetic guideline groups with a useful foundation on which to base their treatment recommendations.

Key Words. Chemotherapy • Emesis • Emetogenicity

This article has been cited by other articles:

				P. J. Hesketh Chemotherapy-Induced Nausea and Vomiting N. Engl. J. Med., June 5, 2008; 358(23): 2482 - 2494. [Full Text] [PDF]

				M. Aapro, S. Grunberg, G. Manikhas, G Olivares, T Suarez, S. Tjulandin, L. Bertoli, F Yunus, B Morrica, F Lordick, et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy Ann. Onc., September 1, 2006; 17(9): 1441 - 1449. [Abstract] [Full Text] [PDF]

				J. Ezzo, A. Vickers, M. A. Richardson, C. Allen, S. L. Dibble, B. Issell, L. Lao, M. Pearl, G. Ramirez, J. A. Roscoe, et al. Acupuncture-Point Stimulation for Chemotherapy-Induced Nausea and Vomiting J. Clin. Oncol., October 1, 2005; 23(28): 7188 - 7198. [Abstract] [Full Text] [PDF]

				P.-B. Tremblay, R. Kaiser, O. Sezer, N. Rosler, C. Schelenz, K. Possinger, I. Roots, and J. Brockmoller Variations in the 5-Hydroxytryptamine Type 3B Receptor Gene as Predictors of the Efficacy of Antiemetic Treatment in Cancer Patients J. Clin. Oncol., June 1, 2003; 21(11): 2147 - 2155. [Abstract] [Full Text] [PDF]

				R. Kaiser, O. Sezer, A. Papies, S. Bauer, C. Schelenz, P.-B. Tremblay, K. Possinger, I. Roots, and J. Brockmoller Patient-Tailored Antiemetic Treatment With 5-Hydroxytryptamine Type 3 Receptor Antagonists According to Cytochrome P-450 2D6 Genotypes J. Clin. Oncol., June 15, 2002; 20(12): 2805 - 2811. [Abstract] [Full Text] [PDF]